Communiqués Indaptus Therapeutics, Inc.

Actions

INDP

US45339J2042

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 13/08/2026			Varia. 5j.	Varia. 1 janv.
1,060 ^USD	+3,92%		-15,20%	-63,57%

05/06	Indaptus Therapeutics, Inc. annonce la démission de plusieurs dirigeants	CI
05/06	Les plus fortes baisses de l'avant-bourse	MT

Communiqués

13/08	Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
15/05	Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
26/03	Indaptus Therapeutics : 10-K 2025 Annual Report	PU
30/12	Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar	AQ
29/12	Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar	AQ
24/12	Indaptus Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
24/12	Indaptus Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
17/11	Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit	AQ
12/11	Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
04/09/25	Indaptus Therapeutics Provides Clinical Update	AQ
02/09/25	Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference	AQ
13/08/25	Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ
01/07/25	Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants	AQ
25/06/25	Indaptus Therapeutics Announces Reverse Stock Split	AQ
16/06/25	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants	AQ
13/06/25	Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants	AQ
02/06/25	Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab	AQ
14/05/25	Indaptus Therapeutics : May 2025 May 2025 Investor Presentation	PU
14/05/25	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update	AQ
08/05/25	Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit	AQ
29/04/25	Indaptus Therapeutics : Notice of 2025 Annual Meeting and Proxy Statement	PU
07/04/25	Indaptus Therapeutics : March 2025 March 2025 Investor Presentation	PU
25/03/25	Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit	AQ
20/03/25	Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20	AQ
18/03/25	Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab	AQ